Mechanistically, CrF‐EVs mitigate colitis and mesenteritis by delivering miR‐132‐3p to LECs and targeting the RASA1/ERK1/2 axis, which promotes lymphangiogenesis and improves lymphatic drainage function. The gene discussed is MAPK3; the disease is colitis.